For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240930:nRSd1235Ga&default-theme=true
RNS Number : 1235G Cirata PLC 30 September 2024
30 September 2024
Cirata plc
("Cirata" or the "Company")
HCSC Contract Renewal
Cirata plc (LSE: CRTA) is pleased to announce that the Health Care Service
Corporation (HCSC) has renewed its existing contract for Cirata's Fusion
product for a period of 12 months. The total consideration for the term is
$983,010. The use case supports HCSC disaster recovery for on-premises Hadoop
data moving to Microsoft Azure cloud. Fusion is a data migration product.
This announcement contains inside information under the UK Market Abuse
Regulation. The person responsible for arranging the release of this
announcement on behalf of Cirata plc is Larry Webster, Company Secretary.
For further information, please contact:
Cirata +1 (925) 380 1728
Stephen Kelly, Chief Executive Officer
Ijoma Maluza, Chief Financial Officer
Daniel Hayes, Investor Relations
FTI Consulting +44 (0)20 3727 1137
Matt Dixon / Kwaku Aning / Usama Ali
Stifel (Nomad and Joint Broker) +44 (0)20 7710 7600
Fred Walsh / Ben Good / Sarah Wong
Panmure Liberum (Joint Broker) +44 (0)20 3100 2000
Max Jones / John More
About Cirata
Cirata, accelerates data-driven revenue growth by automating data transfer and
integration to modern cloud analytics and AI platforms without downtime or
disruption. With Cirata, data leaders can leverage the power of AI and
analytics across their entire enterprise data estate to freely choose
analytics technologies, avoid vendor, platform, or cloud lock-in while making
AI and analytics faster, cheaper, and more flexible. Cirata's portfolio of
products and technology solutions make strategic adoption of modern data
analytics efficient and automated. For more information about Cirata,
visit www.cirata.com (http://www.cirata.com)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END CNTQKCBBBBKDCCB